Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B-Reference-Cited by-同舟云学术

Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B

Published:2014-09-02 Issue:1 Volume:60 Page:260-268
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Tsai Naoky C.,Marcellin Patrick,Buti Maria,Washington Mary Kay,Lee Samuel S.,Chan Sing,Trinh Huy,Flaherty John F.,Kitrinos Kathryn M.,Dinh Phillip,Charuworn Prista,Subramanian G. Mani,Gane Edward

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10620-014-3336-7.pdf

Reference24 articles.

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219.

2. World Health Organization. Hepatitis B: fact sheet no. 204 2013, July 2013. http://www.who.int/mediacentre/factsheets/fs204/en/index.html .

3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.

4. Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682–1683.

5. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has reveal revealed? Liver Int. 2012;32:1333–1341.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in pharmacotherapeutic agents for hepatitis B – how close are we to a functional cure?;Expert Opinion on Pharmacotherapy;2023-05-15

2. Unchanging prevalence of late presentation to care among patients with chronic hepatitis B;Indian Journal of Gastroenterology;2022-08

3. Features of fibrosis regression abound in “non-cirrhotic” patients with resected hepatocellular carcinoma;PLOS ONE;2022-05-12

4. Chronic Hepatitis B;In Clinical Practice;2022

5. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks;World Journal of Clinical Cases;2021-06-26